Nuvalent
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 92
- Market Cap
- $5.4B
- Website
- http://www.nuvalent.com
- Introduction
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC
- Conditions
- Non Small Cell Lung CancerALK-positive Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Nuvalent Inc.
- Registration Number
- NCT06834074
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇬🇧The Royal Marsden Hospital, London, UK, United Kingdom
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
- Conditions
- Non Small Cell Lung CancerROS1-positive Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Nuvalent Inc.
- Registration Number
- NCT06797362
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇳🇱Netherlands Cancer Institute: NKI, Amsterdam, Netherlands
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Conditions
- Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
- Interventions
- Drug: Neladalkib (NVL-655)
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06765109
- Locations
- 🇺🇸
Washington University Center for Advanced Medicine, Saint Louis, Missouri, United States
🇺🇸Clinical Research Alliance Inc., New Hyde Park, New York, United States
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06521554
- Locations
- 🇺🇸
City of Hope - Lennar, Irvine, California, United States
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 470
- Registration Number
- NCT05384626
- Locations
- 🇩🇪
Universitatsklinikum Koln - University Hospital Cologne, Cologne, Germany
🇩🇪Universkitatsklinikum Heidelberg - University Hospital Heidelberg, Heidelberg, Germany
🇯🇵Okayama University Hospital, Okayama, Japan
- Prev
- 1
- 2
- Next